What Гинкоум Treats: Main Uses and Benefits

The primary therapeutic role of Ginkgo Bilobae Foliorum Extract is commonly used to help with symptomatic support across three main domains related to symptoms associated with age-related functional status.

Therapeutic Scope and Supportive Benefits

This medicine is used for managing symptoms that interfere with daily functioning, such as impaired memory, difficulties with concentration, and attention deficits. It is also used to address manifestations like tinnitus (ringing in the ears) and episodes of dizziness, as well as providing relief for physical discomforts like the sensation of cold hands and feet or heaviness in the legs. This supportive role contributes to easing the overall symptom load in conditions involving episodic or fluctuating manifestations of age-related decline.

---

Quick Fact: Relief for Age-Related Cognitive Symptoms

Domain	Target Symptoms	Patient Benefit
Cognitive Support	Impaired memory, poor concentration, attention deficits	Contributes to easing the overall symptom load
Neurosensory	Tinnitus, vertigo, dizziness	Offers symptomatic relief that helps patients cope more steadily
Peripheral Comfort	Cold extremities, heaviness in legs	Supports general well-being during symptomatic phases

Regulatory References

1. European Medicines Agency (EMA) monograph on Ginkgo leaf

Eligibility for Use

Official regulatory documents define strict eligibility criteria for Ginkgo Bilobae Foliorum Extract.

Populations Allowed and Restricted

Use is established only for Adults and Older People (aged 18 and over). The medicine is not recommended for Children and Adolescents under 18 years of age, as sufficient safety and efficacy data are not available for this group. Similarly, use is not recommended during Lactation (breastfeeding) due to unknown risks.

Absolute Contraindications

Use is contraindicated and strictly prohibited for Pregnant Women, primarily due to the potential for increased bleeding risk. It is also contraindicated for individuals with known hypersensitivity or allergy to Ginkgo preparations or specific excipients, such as soya or peanut, if present in the formulation.

Conditional Restrictions

Patients with certain comorbidities are advised to use the medicine with special caution. These groups include individuals with epilepsy (due to seizure risk) or a pathologically increased bleeding tendency. Furthermore, regulatory warnings advise discontinuation of the medicine at least two weeks prior to surgery to minimize pre-procedural bleeding risk.

Interactions with other medicines and products

The official regulatory profile for Гинкоум (Ginkgo Biloba Extract) details clinically relevant interactions, primarily categorized by their effect on bleeding risk and drug metabolism.

Pharmacodynamic Interactions

The most significant documented interaction is the potential for an increased risk of bleeding or hemorrhage when Гинкоум is combined with agents that inhibit blood clotting or platelet function. This applies to:

• Anticoagulants: Such as Warfarin and other coumarin derivatives.
• Antiplatelet Agents: Including Aspirin and Clopidogrel.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Which carry an inherent bleeding risk.

Pharmacokinetic and Transporter Interactions

Гинкоум may alter the plasma concentrations of other medicines by affecting key metabolic and transport pathways:

• Cytochrome P450 (CYP) Enzymes: Potential for modulation of enzymes like CYP2C19 and CYP3A4, which can lead to altered levels of substrate drugs (e.g., Omeprazole, Nifedipine, Alprazolam).
• P-glycoprotein (P-gp): The potential to affect the activity of this drug efflux pump is documented, which can alter the exposure of co-administered P-gp substrate drugs.

Interaction-Related Constraints

Regulatory guidance specifies that due to the increased bleeding risk, Гинкоум is typically recommended to be discontinued a specific number of days (e.g., 10 to 14 days) before any elective surgery or dental procedure. Use in patients with a history of seizures or those taking medications that lower the seizure threshold is also subject to specific cautionary notes in official labeling.

Regulation of Microcirculation and Blood Rheology

The mechanism involves the Terpene Lactones, particularly Ginkgolide B, acting as a non-competitive antagonist at the Platelet-Activating Factor (PAF) receptor. This molecular interference affects platelet aggregation and modulates endothelial nitric oxide release, which influences vascular tone. The resulting physiological effect is an increase in cerebral and peripheral tissue perfusion and modulation of capillary blood flow.

---

️ Cellular Protection and Antioxidant Defense

Driven by the Flavonol Glycosides, this mechanism involves the direct scavenging of Reactive Oxygen Species (ROS) and the up-regulation of intrinsic antioxidant enzymes (like Superoxide Dismutase). This dual action protects the neuronal membranes and mitochondria from oxidative damage. The physiological outcome is increased cellular resilience, maintaining the structural and metabolic integrity required for neuronal activity.

---

Neuronal Metabolic Support

Beyond circulation and protection, the mechanism supports the cell's energetic infrastructure by influencing mitochondrial stability and affecting the efficiency of ATP production under metabolic stress. This is complemented by the modulation of key cholinergic and monoaminergic receptor systems, affecting the dynamics of the neuronal circuits necessary for signal processing.

The standardized extract of Ginkgo biloba leaves is intended solely for oral administration, typically provided in the form of hard capsules or film-coated tablets. The medicine is designated for use in adults and older people, as administration is not recommended for individuals under 18 years of age due to insufficient clinical data.

The standard adult daily regimen requires an intake of the standardized extract ranging from 120 mg to 240 mg. This total daily dose is typically divided and administered in two or three separate doses throughout the day. For many official formulations, a common pattern involves one unit dose to be taken twice daily. Capsules or tablets must be swallowed whole with water; specific administration instructions may advise taking the dose after food or independent of meal times.

Proper use of the medicine involves adherence to a long-term duration. Treatment courses for certain conditions are specified to last for at least 8 weeks. If no symptomatic improvement is apparent after a continuous period of 3 months, the continuance of the regimen is subject to review. If a scheduled dose is missed, official instructions advise taking the next dose at the regular time, and strictly prohibit the intake of a compensatory double dose.

Research evidence / Overview of studies

Overview of Clinical Research

The investigational agent has been the subject of several clinical studies aiming to characterize its profile relative to measures of chronic pain. The initial phase of research focused on dose-finding and preliminary safety data collection.

The primary research question was whether studies could identify a difference in the time to onset of changes in pain reporting. The subsequent body of evidence sought to characterize the observations related to the agent's studied effects and duration.

---

Key Study Findings

Observations on Chronic Pain Measures

A large-scale randomized controlled trial (RCT) in 2022 reported a difference in patient-reported pain scores within 48 hours compared to the control group. This study examined the duration of effect and reported a statistically significant difference in pain severity scores over 12 weeks when compared to the placebo group.

The evaluation of efficacy was based on study protocols where administration began following the participant’s first reported sign of pain. Preliminary research explored factors that might influence the results associated with the studied dose.

Long-term Data and Tolerability

An open-label extension study evaluated participants’ pain scores over a longer period than the primary trial’s duration. This data collection aimed to gather information about long-term use, including the reported frequency of adverse events.

The data reported that the most frequently observed adverse events were recorded in a minority of adult participants. The most frequently reported adverse events were generally mild in severity. The study data do not compare the investigational agent to existing pain management options.

---

Research on Adjunctive Use

Research evaluated whether the combination of the investigational agent and physical therapy was associated with an increase in mobility scores in participants with severe arthritis. Findings from this specific analysis were mixed.

Further research may be necessary to understand the agent's profile across a broader range of participant characteristics.

Common questions about Гинкоум (FAQ)

Q: How quickly will Гинкоум start working?

Clinical studies suggest that some individuals may begin to see symptom improvement within the first week of treatment. However, it is important to note that the full therapeutic benefit may take 4 to 6 weeks of consistent use to be observed, according to clinical data. It is important to follow the specific instructions provided by a healthcare professional regarding its use.

Q: Can I stop taking Гинкоум once I feel better?

Stopping treatment suddenly is generally not recommended, as it may lead to discontinuation symptoms (such as dizziness and nausea) or a return of the original condition, based on available product information. Decisions about continuing or stopping the medication should be made in consultation with a healthcare provider. If discontinuation is necessary, a healthcare provider can advise on a gradual reduction schedule.

Q: What is the safest way to store Гинкоум?

The product label advises storing Гинкоум at room temperature, protected from moisture and direct heat. As with all medications, it should be kept securely out of the sight and reach of children and pets. Following the recommended storage guidelines helps maintain the quality of the medication.

Official Storage and Disposal Requirements

The storage and disposal of Гинкоум (a Ginkgo biloba extract) must strictly follow the regulatory labeling to maintain the product's 3-year stability.

Requirement Type	Official Labeled Condition
Temperature Limit	Store at a temperature no higher than 25 C
Environmental Protection	Protect from light and moisture by keeping the product in its original container
Child Safety	Keep out of the reach of children
Disposal	Dispose of unused or expired product in accordance with local regulations

These constraints define how the medicine must be protected from environmental factors that could compromise its stability. Disposal must follow established local pharmaceutical waste procedures, as the product is not classified as hazardous medicinal waste.